Monte Rosa Therapeutics, Inc. income statement GLUE

Annual Quarterly

In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, Monte Rosa Therapeutics, Inc. reported revenue of $54.4 million, up 325.8% from the same quarter a year earlier. Net income was $3.1 million, a profit margin of 5.6%. The operating loss came to $1.9 million, an operating margin of -3.6%.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the same quarter a year earlier.

TTM
Sep 30, 2026
Q3 FY2026
Sep 30, 2026
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2025
Sep 30, 2025
Q2 FY2025
Jun 30, 2025
Q1 FY2025
Mar 31, 2025
Q4 FY2024
Dec 31, 2024
Revenue
70
-61.3%
54
+325.8%
9
-61.3%
4
-95.0%
3
-95.4%
13
+38.5%
23
+394.0%
85
+7882.0%
61
Research and development
179
+29.6%
45
+23.7%
48
+56.5%
44
+36.9%
42
+8.0%
37
+32.8%
31
+9.3%
32
+19.1%
39
+43.2%
Selling, general and administrative
42
+20.6%
11
+20.7%
10
+25.2%
10
+16.9%
11
+19.8%
9
+11.5%
8
-12.8%
9
-3.1%
9
+13.6%
Operating income
-151
-1872.0%
-2
+94.1%
-49
-215.9%
-50
-213.6%
-50
-482.3%
-33
-24.3%
-16
+52.3%
44
+226.0%
13
+137.3%
Other income (expense)
21
+55.3%
6
+110.5%
6
+33.3%
6
+52.1%
4
+40.1%
3
-0.8%
4
+72.5%
4
+19.9%
3
+63.4%
Pretax income
-130
-691.9%
4
+112.5%
-43
-289.2%
-44
-193.2%
-46
-395.3%
-30
-27.2%
-11
+63.1%
48
+249.6%
16
+146.9%
Income tax
1
+2.7%
1
+122.5%
0
-82.7%
0
-93.7%
0
-97.3%
-3
-4574.6%
1
+375.8%
1
+890.4%
2
+9936.4%
Net income
-131
-725.2%
3
+111.3%
-43
-253.0%
-45
-194.9%
-46
-443.1%
-27
-13.5%
-12
+59.4%
47
+246.7%
13
+140.4%
Basic EPS
-1.35
-629.0%
—
—
—
—
—
—
—
—
Diluted EPS
-1.36
-635.2%
—
—
—
—
—
—
—
—
Weighted average shares, basic
97
+18.2%
102
+23.5%
101
+23.5%
100
+21.6%
86
+4.2%
82
+0.5%
82
+15.4%
82
+36.6%
82
+44.1%
Weighted average shares, diluted
97
+16.8%
109
+31.8%
101
+23.5%
100
+20.4%
83
+1.7%
82
+0.5%
82
+15.4%
83
+37.9%
82
+44.1%
Other measures
Depreciation and amortization
8
-1.8%
2
+2.3%
2
-10.1%
2
-0.9%
2
+1.3%
2
-0.4%
2
+3.2%
2
+8.0%
2
+11.6%
EBITDA
-143
-947.0%
0
+100.7%
-47
-251.6%
-48
-204.2%
-48
-416.1%
-31
-26.4%
-13
+56.1%
46
+239.4%
15
+145.6%
Margins
Operating margin
-214.46%
-3.57%
-547.84%
-1,188.46%
-1,787.67%
-258.26%
-67.06%
51.85%
21.44%
Pretax margin
-184.77%
6.95%
-481.59%
-1,055.84%
-1,656.81%
-236.98%
-47.84%
56.17%
25.72%
Profit margin
-186.20%
5.63%
-483.91%
-1,057.08%
-1,658.00%
-212.10%
-53.01%
55.20%
22.16%
EBITDA margin
-202.83%
0.38%
-526.53%
-1,140.26%
-1,712.59%
-241.85%
-57.90%
54.26%
24.84%
Effective tax rate
—
18.95%
—
—
—
—
—
1.72%
13.87%
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
GLUE (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Boston, MA
SEC filer status
, Emerging growth company
SEC CIK
1826457
Former names
Monte Rosa Therapeutics, Inc. (until Nov 5, 2026)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.